Benefit of Apabetalone on Plasma Proteins in Renal Disease.

ABSTRACT:

Introduction

Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone has in vitro and in vivo anti-inflammatory and antiatherosclerotic properties. In phase 2 clinical trials, this drug reduced the incidence of major adverse cardiac events in patients with cardiovascular disease. Chronic kidney disease is associated with a progressive loss of renal function and a high risk of cardiovascular disease. We studied the impact of apabetalone on the plasma proteome in patients with impaired kidney function.

Methods

Subjects with stage 4 or 5 chronic kidney disease and matched controls received a single dose of apabetalone. Plasma was collected for pharmacokinetic anal

SUBMITTER: Wasiak S 

PROVIDER: S-EPMC5976837 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature